Phase 3 Data Shows D-PLEX100 Sustains 32-Day Doxycycline Release; Analysts Moderate Buy
PolyPid will present new Phase 3 SHIELD II pharmacokinetic data at ESCMID Global 2026 showing D-PLEX100 delivered continuous doxycycline release for up to 763 hours with plasma levels below 100 ng/mL. Six analysts covering PolyPid maintain a moderate buy consensus, with five buy and one sell recommendation.
1. SHIELD II Pharmacokinetic Results
PolyPid’s SHIELD II trial data demonstrate that D-PLEX100 maintains detectable doxycycline concentrations at the surgical incision site for 763 hours (approximately 32 days) without an initial burst release. Plasma doxycycline levels remained below 100 ng/mL, markedly lower than oral dosing Cmax values of 1,613 ng/mL (100 mg) to 2,600 ng/mL (200 mg), indicating minimal systemic exposure.
2. Analyst Consensus Rating
Among the six research firms covering PolyPid, five have issued buy recommendations and one a sell, resulting in an overall moderate buy consensus. This sentiment reflects cautious optimism as the company advances its lead asset through regulatory and clinical milestones.